GLYCOMIMETICS INC (GLYC) Stock Price, Quote, News and Overview
NASDAQ:GLYC - Nasdaq - US38000Q1022 - Common Stock - Currency: USD
GLYC Quote, Performance and Key Statistics
GLYCOMIMETICS INC
NASDAQ:GLYC (2/18/2025, 4:36:26 PM)
After market: 0.34 -0.02 (-5.56%)0.36
+0.07 (+24.14%)
The current stock price of GLYC is 0.36 USD. In the past month the price increased by 38.08%. In the past year, price decreased by -87.62%.
GLYC Latest News, Press Relases and Analysis
Wondering what's happening in today's pre-market session?
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
What's going on in today's after hours session
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
What's going on in today's after hours session
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week
From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.
GLYC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.39 | 346.80B | ||
| AMGN | AMGEN INC | 14.77 | 157.23B | ||
| GILD | GILEAD SCIENCES INC | 22.83 | 131.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1593.48 | 118.72B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.9 | 74.34B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.83B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.24B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.43B | ||
| ONC | BEIGENE LTD-ADR | N/A | 25.41B | ||
| NTRA | NATERA INC | N/A | 22.36B | ||
| BIIB | BIOGEN INC | 8.29 | 19.90B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.37 | 16.64B |
Related stock screener links
About GLYC
Company Profile
GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. The company is headquartered in Rockville, Maryland and currently employs 35 full-time employees. The company went IPO on 2014-01-10. The company is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. The company is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. The company has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4).
Company Info
GLYCOMIMETICS INC
9708 Medical Center Drive
Rockville MARYLAND 20850 US
CEO: Rachel K. King
Employees: 35
Company Website: https://glycomimetics.com/
Investor Relations: http://ir.glycomimetics.com/
Phone: 12402431201
GLYC FAQ
What is the stock price of GLYC?
The current stock price of GLYC is 0.36 USD.
What is the symbol for GLYCOMIMETICS INC stock?
The exchange symbol of GLYCOMIMETICS INC is GLYC and it is listed on the Nasdaq exchange.
On which exchange is GLYC stock listed?
GLYC stock is listed on the Nasdaq exchange.
Is GLYC a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for GLYC, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of GLYC.
Does GLYC stock pay dividends?
GLYC does not pay a dividend.
When does GLYC stock report earnings?
GLYC will report earnings on 2025-03-25, after the market close.
What is the Price/Earnings (PE) ratio of GLYC?
GLYC does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).
What is the Short Interest ratio of GLYC stock?
The outstanding short interest for GLYC is 3.25% of its float.
GLYC Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to GLYC. When comparing the yearly performance of all stocks, GLYC is a bad performer in the overall market: 93.45% of all stocks are doing better.
GLYC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GLYC. While GLYC seems to be doing ok healthwise, there are quite some concerns on its profitability.
GLYC Financial Highlights
Over the last trailing twelve months GLYC reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS increased by 6.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -160.17% | ||
| ROE | -194.94% | ||
| Debt/Equity | 0 |
GLYC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to GLYC. The Buy consensus is the average rating of analysts ratings from 7 analysts.